NCT06151587
A Phase 3 Clinical Study of QLM3004 in Delaying Myopia in Children
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Different Concentrations of QLM3004 in Delaying the Progression of Myopia in Children
Qilu Pharmaceutical Co., Ltd.·Phase 3·ClinicalTrials.gov·drugRecruiting
View on ClinicalTrials.gov →Study focus
- Disease/Condition
- Myopia
- Drug/Device/Intervention
- QLM3004 Concentration 1
- Study type
- Interventional
- Intervention type
- drug
Sponsor & location
- Primary sponsor
- Qilu Pharmaceutical Co., Ltd.
- Location
- Wenzhou, China
Timeline & enrollment
- Phase
- Phase 3
- Start date
- Aug 20, 2023
- End date
- Jun 01, 2027
- Enrollment
- 735 participants
Primary outcome
Change from Baseline in spherical equivalent determined by cycloplegic autorefraction at week 96.
Summary
Efficacy and Safety Study of QLM3004 in Myopic Children
ICD-10 classifications
MyopiaDegenerative myopiaAmblyopia ex anopsiaOcular myiasisMyiasis
Data source
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT06151587
- Type
- Non-Device Trial
About this record
Access comprehensive clinical trial information for NCT06151587 through Pure Global AI's free database. This Phase 3 trial is sponsored by Qilu Pharmaceutical Co., Ltd. and is currently Recruiting. The study focuses on Myopia. Target enrollment is 735 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.